Physician profile
Nizar A Assi
NPI 1194772954
$80,895.05
in general payments reported to CMS, 2019-2025
25 companies · $3,132 in 2025
The $3,132 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $31K · 2021: $23K · 2022: $620 · 2023: $228 · 2024: $926 · 2025: $3,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,999 · Travel and Lodging: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,998.58 |
| Travel and Lodging | $1,288.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49,372.62 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $12,978.51 | 2020-2022 | |
| Lilly USA, LLC | $11,778.48 | 2019-2021 | |
| Medtronic, INC. | $4,319.81 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Omniasecure Mri Surescan |
| Abiomed | $925.34 | 2021-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $293.57 | 2019-2025 | |
| Abbott Laboratories | $234.25 | 2019-2023 | Perclose Prostyle |
| Boston Scientific Corporation | $198.98 | 2024-2025 | Eluvia, Synergy, Angiojet Ultra 5000a |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.95 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $156.50 | 2025 | Assure Wcd |
| Amgen INC. | $106.90 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $59.43 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $58.99 | 2019-2022 | |
| Philips North America LLC | $53.98 | 2021-2024 | (792) Multi Modality Ivus Other Systems |
| Amarin Pharma, INC. | $47.02 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $27.65 | 2019 | |
| Bard Peripheral Vascular, INC. | $21.80 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $21.44 | 2019 | |
| Gilead Sciences, INC. | $18.19 | 2019 | |
| Merck Sharp & Dohme LLC | $17.46 | 2021 | |
| Asahi Intecc USA, INC. | $14.92 | 2025 | Asahi Coronary Wires |
| Pfizer INC. | $13.17 | 2019 | |
| Circassia INC. | $12.09 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nizar Assi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.